No connection

Search Results

BGM vs KURA

BGM
BGM Group Ltd.
BEARISH
Price
$3.72
Market Cap
$746.3M
Sector
Healthcare
AI Confidence
85%
KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BGM
--
KURA
--
Forward P/E
BGM
--
KURA
-3.55
P/B Ratio
BGM
2.01
KURA
4.37
P/S Ratio
BGM
24.99
KURA
11.35
EV/EBITDA
BGM
-29.15
KURA
-0.39

Profitability

Gross Margin
BGM
2.92%
KURA
-272.14%
Operating Margin
BGM
-5.41%
KURA
-497.62%
Profit Margin
BGM
-26.32%
KURA
0.0%
ROE
BGM
-16.52%
KURA
-94.82%
ROA
BGM
-3.84%
KURA
-25.33%

Growth

Revenue Growth
BGM
-56.9%
KURA
-67.8%
Earnings Growth
BGM
0.0%
KURA
--

Financial Health

Debt/Equity
BGM
0.0
KURA
0.12
Current Ratio
BGM
7.05
KURA
6.06
Quick Ratio
BGM
5.94
KURA
5.81

Dividends

Dividend Yield
BGM
--
KURA
--
Payout Ratio
BGM
0.0%
KURA
0.0%

AI Verdict

BGM BEARISH

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health relative to distressed peers
Exceptionally strong liquidity with a Current Ratio of 7.05 and Quick Ratio of 5.94
Zero debt (Debt/Equity = 0.00), reducing solvency risk
Risks
Severe profitability issues: -26.32% profit margin and -16.52% ROE
Catastrophic revenue decline of -56.90% YoY, far worse than peer average
Price/Sales of 24.99 is extremely high for a shrinking, unprofitable company
KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)

Compare Another Pair

BGM vs KURA: Head-to-Head Comparison

This page compares BGM Group Ltd. (BGM) and Kura Oncology, Inc. (KURA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile